The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A novel 95-gene signature (Curebest 95GC Breast) that predicts recurrence-risk in patients with ER-positive, HER2-negative, node-negative, early-stage primary invasive breast cancer with an intermediate Oncotype DX Recurrence Score.
 
Takeo Fujii
No Relationships to Disclose
 
Hiroko Masuda
No Relationships to Disclose
 
Yee Chung Cheng
No Relationships to Disclose
 
Fei Yang
No Relationships to Disclose
 
Aysegul A. Sahin
No Relationships to Disclose
 
Yasuto Naoi
Consulting or Advisory Role - Sysmex
Research Funding - Sysmex
 
Yuki Matsunaga
No Relationships to Disclose
 
Akshara Singareeka Raghavendra
No Relationships to Disclose
 
Arup Kumar Sinha
No Relationships to Disclose
 
Jose R. Espinosa Fernandez
No Relationships to Disclose
 
Anjali James
No Relationships to Disclose
 
Keisuke Yamagishi
Employment - Sysmex
 
Tomoko Matsushima
Employment - Sysmex
Stock and Other Ownership Interests - Sysmex
 
Debu Tripathy
Consulting or Advisory Role - CellMax Life; Genomic Health; GlaxoSmithKline; Nektar; Novartis; Pfizer; Polyphor; Puma Biotechnology; Sellas Life Sciences
Research Funding - Genentech/Roche (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Novartis
 
Sachiyo Tada
Employment - Sysmex
Stock and Other Ownership Interests - Sysmex
 
Rubie S. Jackson
No Relationships to Disclose
 
Shinzaburo Noguchi
Honoraria - Sysmex
Research Funding - Sysmex
Patents, Royalties, Other Intellectual Property - Sysmex
 
Seigo Nakamura
Honoraria - AstraZeneca; Chugai Pharma; Pfizer; Taiho Pharmaceutical
 
Jared David Acoba
No Relationships to Disclose
 
Naoto T. Ueno
Honoraria - Amgen; Chugai Pharma; Kyowa Hakko Kirin; Roche
Consulting or Advisory Role - Samsung Bioepis
Research Funding - Amgen; Bayer; Bio-Path Holdings; Celgene; Daiichi Sankyo; GlaxoSmithKline; Kyowa Hakko Kirin; Medivation; Merck; Novartis; Puma Biotechnology; Sysmex
Travel, Accommodations, Expenses - Kyowa Hakko Kirin